Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
The Lancet. Oncology|April 30, 2022
Time to deterioration of symptoms or function using patient-reported outcomes in cancer trialsMallorie H Fiero, Jessica K Roydhouse, Vishal Bhatnagar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2026
FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle Invasive Bladder CancerNooshin Mirkheshti, Daniel Edem Kpormegbey, Chana Weinstock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer Survivors Reporting Cognitive Symptoms After ChemotherapyVictoria J Bray, Haryana M Dhillon, Melanie L Bell, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|April 2, 2022
US Food and Drug Administration Analysis of Patient-Reported Diarrhea and Its Impact on Function and Quality of Life in Patients Receiving Treatment for Breast CancerTing-Yu Chen, Bellinda L King-Kallimanis, Lyna Merzoug, et al.
The Lancet. Oncology|October 1, 2020
Demystifying the estimand framework: a case study using patient-reported outcomes in oncologyMallorie H Fiero, Madeline Pe, Chana Weinstock, et al.
Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc|May 9, 2025
Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled AnalysisAsma Dilawari, Mori J Krantz, Ilynn Bulatao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 9, 2024
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell CarcinomaJaleh Fallah, Brian L Heiss, Hee-Koung Joeng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2022
FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast CancerMirat Shah, Christy L Osgood, Anup K Amatya, et al.
JAMA Oncology|January 6, 2022
Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy: A Pooled Analysis of Trials in the US Food and Drug Administration DatabaseMitchell S Anscher, Shaily Arora, Chana Weinstock, et al.
The Oncologist|December 16, 2017
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M MutationLauretta Odogwu, Luckson Mathieu, Kirsten B Goldberg, et al.
Pageof 5